Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Affectis Pharmaceuticals AG
Dortmund, Nordrhein-Westfalen, Germanyaffectis.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Affectis Pharmaceuticals AG is a German biopharmaceutical company focused on developing novel small molecule drugs targeting neurodegenerative, neuroinflammatory, and psychiatric disorders. Its lead assets target the P2X7 receptor and COX‑2, with at least one program having reached Phase 2 clinical trials in depression. The company has also developed brain‑penetrant oral compounds and has ongoing collaborations to advance its pipeline.[1][9][10]
- Therapeutic areas
- EndocrinologyPsychiatryNeurology
- Modalities
- Small molecules[1][2][5]
- Industry
- Biotech
02
Partnerships
Merck Serono(agreement to develop oral drugs for neurodegenerative diseases targeting theP₂ X₇receptor )[1 ]Dalton Pharma Services(contract services agreement )[1 ]Lead Discovery Center GmbH(close collaboration since2014 )[5 ]
Beyond the preview
Go deeper on Affectis Pharmaceuticals AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affectis Pharmaceuticals AG.